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Abstract
Background: Lunasin is a chemopreventive peptide produced in a number of plant species. It comprises a helical
region with homology to a region of chromatin binding proteins, an Arg-Gly-Asp cell adhesion motif and eight
aspartic acid residues. In vitro studies indicate that lunasin suppresses chemical and oncogene driven
transformation of mammalian cells. We have explored efficient recombinant production of lunasin by exploiting
the Clostridium thermocellum CipB cellulose binding domain (CBD) as a fusion partner protein.
Results: We used a pET28 vector to express a CBD-lunasin fusion with a hexahistidine tag and Tobacco Etch Virus
protease site, to allow protease-mediated release of native lunasin. Autoinduction in E. coli BL21 (DE3) Star cells
achieved expression of 3.35 g/L of CBD-lunasin fusion protein. The final yield of lunasin was 210 mg/L
corresponding to 32% of the theoretical yield. Purification by cellulose binding and nickel affinity chromatography
were tested with the latter proving more satisfactory.
The effects of CBD-lunasin expression on growth and morphology of the E. coli cells were examined by light and
electron microscopy revealing an altered morphology in a proportion of cells. Cell division appeared to be
inhibited in these cells resulting in elongated, non-septated cells.
Conclusions: The use of CBD as a fusion partner gave high protein yields by autoinduction, with lunasin release
by TEV protease cleavage. With some optimisation this approach could provide a potentially valuable route for
production of this therapeutic peptide. Over-expression in the host cells manifest as a cell division defect in a
population of the cells, presumably mimicking some aspect of the chemopreventive function observed in
mammalian cells.
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Background
Lunasin is a 43 amino acid chemopreventive peptide
initially identified in soybean and more recently in bar-
ley, wheat, and Solanum nigrum [1]. It is a small subunit
peptide derived from the larger cotyledon-specific 2S
albumin (Gm2S-1) complex and comprises three distinct
regions. An N-terminal helical region that shares homol-
ogy with the conserved region of the chromatin binding
proteins, an Arg-Gly-Asp (RGD) cell adhesion motif and
a C-terminal sequence of eight aspartic acid (D) residues
[2]. Various studies have shown the ability of lunasin to
suppress both chemical and oncogene driven transfor-
mation of mammalian cells. The chemopreventive
properties have also been illustrated in mouse skin can-
cer models where lunasin has been shown to suppress
transformation and subsequent carcinogenesis [3]. The
proposed biological activityo ft h er e g i o n so fl u n a s i ni s
shown in Figure 1.
There are two broad strategies for the production of
therapeutic peptides and proteins: chemical synthesis
and recombinant production by transgenic organisms
ranging from bacteria and fungi to plants and animals.
Chemical synthesis is rapid and effective for the produc-
tion of custom-made peptides in relatively small quanti-
ties but can be costly and problematic during process
scale-up and as amino acid sequence length increases
with sequences over 35 amino acids not generally con-
sidered to be economically feasible [5]. In addition, the
process employs chemicals that present potential envir-
onmental hazards. The use of microbial ‘biofactories’ for
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to their ease of use, robustness and costs. Recombinant
systems are more effective for the production of long
peptides (> 35 amino acids) and proteins.
The Gram-negative bacterium E. coli is one of the
most attractive systems for heterologous protein pro-
duction due to its ability to grow rapidly to a high cell
density on inexpensive substrates and it is genetically
well characterised. A common strategy for the produc-
tion of recombinant peptides involves genetic attach-
ment to a well expressed protein to generate a fusion
protein. The protein acts to protect the peptide from
proteolytic digestion and can protect the host from
potential toxicity associated with some peptides. There
are a number of fusion partner proteins available
which differ in size and properties; some facilitate
soluble expression while others promote the formation
of inclusion bodies [6-8].
Previous reports of lunasin expression in E. coli have
included its fusion to an 8 amino acid FLAG peptide
epitope to allow antibody detection. It was observed that
the DH5a host exhibited poor growth and an inability
to septate, resulting in the formation of filamentous
cells [9]. In another study, lunasin was expressed as a
fusion to green fluorescent protein (GFP) using an in
vitro transcription/translation reaction. While reasonable
protein yields of 270 μg of purified GFP-lunasin protein
were obtained from a 10 mL reaction, this only equates
to 27 mg/L of fusion protein and a theoretical maxi-
mum of 4.1 mg of lunasin peptide. In addition the
equipment and reagents required for this system are
expensive which is likely to limit scale-up [10]. More
recently lunasin has been expressed with a C-terminal
His-tag in a soluble form and purified by immobilized
metal affinity chromatography. Using an E. coli T7 sys-
tem with IPTG induction, 4.73 mg of lunasin was
expressed/L of culture [11]. This study showed that bac-
terial growth and expression levels were not affected by
the presence of lunasin. In the present study, to enhance
the levels of production of lunasin we have investigated
t h eu s eo faH i s - t a g g e dClostridium thermocellum CipB
cellulose binding domain (CBD) as a fusion protein and
purification tag for the production of the native thera-
peutic peptide lunasin.
Results
Cloning of CBD-lunasin into pET28c
The lunasin coding sequence with an N-terminal six
h i s t i d i n et a ga n dT E Vp r o t e a s e( T E V p )s i t ew a sc o n -
structed by recursive PCR using the primers, EcHisTEV-
lunF and EcHisTEVlunR. This fragment was then
cloned into pET28 downstream of the CBD coding
region. DNA sequence analysis confirmed the integrity
of the construct. Figure 2 shows a schematic representa-
tion of the recombinant protein expression and peptide
release strategy.
Expression of CBD-lunasin fusion protein from E. coli
BL21* (DE3) by auto-induction
Auto-induction allows cultures to reach very high cell
densities before recombinant protein expression occurs
[12]. This approach reduces the risk of cell toxicity
while enhancing product recovery.
Initial expression trials with TB media were con-
ducted over a period of 72 h at 25°C. This temperature
has previously been shown to be optimal for the pro-
duction of soluble CBD and CBD fusions within the
laboratory (unpublished observations). It was apparent
Figure 1 Amino acid sequence of lunasin and activity of
regions of the peptide. Lunasin is a 43-amino acid peptide
consisting of four regions. The function of residues 1-22 is currently
unknown. Residues 23-31 target lunasin to chromatin. The Arg-Gly-
Asp cell recognition sequence of residues 32-34 is known to
internalise lunasin into the cell nucleus. The poly-aspartyl end of
lunasin (residues 35-43) is responsible for binding it to the core
histones within the chromatin. Adapted from [4].
Figure 2 Expression strategy of the CBD-lunasin fusion protein
and subsequent TEV cleavage. The arrangement of regions of the
construct are shown. Lunasin peptide released following TEV
cleavage has the native sequence as the N-terminal serine residue is
provided by the TEV protease recognition sequence. Also indicated
are the expected sizes of the resulting fragments.
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fusion protein was in the soluble fraction with yields
reaching 1.4 g/L between 60 and 72 h of growth (Fig-
ure 3A).
From the work of Studier [12] and previous studies in
our laboratory [13,14], it was clear that alternative basal
media together with increased levels of carbon source
could result in increased yields of fusion protein.
This was investigated with cultures grown over a per-
iod of 96 h at 25°C in four different media (TB, 4ZY,
8ZY and 8ZY). Samples were taken at regular intervals,
and the culture optical densities at 600 nm (Figure 3B)
and protein yields (Figure 3C) were determined. Maxi-
mal culture densities were obtained following 72 h
growth at 25°C, in 8ZY medium supplemented with 4 ×
5052 (2% glycerol, 0.2% glucose, 0.8% a-lactose mono-
hydrate) and 25 mM succinate (Table 1) [12]. This cul-
ture reached very high culture densities with an OD600
value of 53. SDS-PAGE analysis in conjunction with
quantification of yields by densitometry revealed that
this medium resulted in the production of 3.35 g/L of
CBD fusion protein at 72 h. Purification of the CBD-
lunasin fusion protein resulted in a yield of 51.5% which
equates to a maximum theoretical lunasin yield of 350
mg/L.
Purification of CBD-lunasin fusion protein by batch
binding to cellulose
The low cost of cellulose makes this an attractive purifi-
cation matrix and so we explored the recovery of the
Figure 3 Expression of CBD-lunasin constructs and protein recovery. ( A )S D S - P A G Ea n a l y s i so fs o l u b l eand insoluble fractions of E. coli
BL21*(DE3) carrying pET28-CBD-lunasin grown on 8ZY auto-induction media supplemented with 4 × 5052 and succinate at 25°C. (B) Time-
course of cell growth as OD600 in various auto-induction media at 25°C (C) SDS-PAGE analysis of the CBD-lunasin fusion protein purified using
cellulose phosphate batch binding, cleavage by TEV protease and either a Microcon
® concentrator column or Ni-NTA agarose step. (D) CBD-
lunasin fusion protein yield over time-course in (B).
Table 1 Components of auto-induction media.
Medium components Growth Medium
TB 4ZY 8ZY 8ZY + succinate
Tryptone (g/L) [Z] 12 40 80 80
Yeast extract (g/L) [Y] 24 20 40 40
NPCS (mM)
Na2HPO4 25 25 25 25
KH2PO4 25 25 25 25
NH4CI 50 50 50 50
Na2SO4 55 5 5
MgSO4(mM) 2 2 2 2
Trace metals 0.2× 0.2× 0.2× 0.2×
5052 (%)
Glycerol 2 2 2 2
Glucose 0.2 0.2 0.2 0.2
Lactose 0.8 0.8 0.8 0.8
Succinate (mM) - - - 25
Adapted from [12]
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supernatant was diluted 2-fold with 200 mM Tris-HCl
(pH 7.0) and prewetted cellulose phosphate was added
to a final concentration of 200 mg/mL. After binding
overnight at room temperature, the cellulose phosphate
was washed twice with 100 mM Tris-HCl (pH 7.0) (Fig-
ure 3D). A number of elution steps typically 4, each
with 25 mL, water were required to release around 50
mg of the protein thus resulting in a significant dilution
of the fusion protein.
We therefore explored purification using nickel affi-
nity chromatography (Ni-NTA) by exploiting the histi-
dine tag. This allowed the more efficient recovery of
concentrated fusion protein, with some evidence on
SDS-PAGE of dimers and trimers of the fusion protein
(Figure 3D).
TEV cleavage of the lunasin peptide from the CBD
fusion protein results in release of lunasin with a native
N-terminal serine provided by the TEV protease site
ENLYFQ/S (Figure 2). TEV protease cleavage was con-
ducted at room temperature over a 24 h time-period
with a TEV protease concentration of 700 nM. Reason-
ably efficient cleavage was achieved although low levels
of uncleaved fusion protein remained (Figure 3D). The
dimeric form of the fusion protein appeared not to be
susceptible to cleavage perhaps due to steric interactions
between monomers occluding the protease sites.
Following TEV cleavage the lunasin peptide was sepa-
rated from CBD, TEVp and uncut CBD-lunasin. Two
approaches were investigated; the first was Microcon
®
centrifugal filter devices that have a cellulose matrix act-
ing as a molecular sieve to allow passage of molecules
of less than 10 kDa, such as lunasin, whilst retaining lar-
ger molecules. The second approach was Ni-NTA agar-
ose batch binding as all the proteins contain a His tag
whilst lunasin does not and so would remain in solution
(Figure 3D).
The Microcon
® centrifugal approach was ineffective as
the majority of the peptide was retained. In contrast,
batch binding with the Ni-NTA agarose proved to be
quite efficient with 60% of the lunasin being recovered,
corresponding to a yield of 210 mg/L culture.
To confirm the molecular mass and purity of the final
lunasin product, mass spectrometry was performed and
revealed a single major peak corresponding to 5024.09
Da in excellent agreement with the calculated mass of
5028.36 Da.
Effect of lunasin on E. coli cell morphology
To check for any effect of the CBD-lunasin fusion on
the growth and morphology of the E. coli BL21*(DE3)
host cells, culture pellets were re-suspended in water
and Gram stained (Figure 4A). By light microscopy it
was apparent that expression of the CBD-lunasin fusion
protein resulted in an altered morphology of some cells.
Cell division appeared to be inhibited in a proportion of
the cells resulting in elongated, non-septated cells with
lengths of over 100 μM. In comparison, a Gram stain of
E. coli BL21* (DE3) expressing CBD alone did not show
such elongated, non-septate cells (Figure 4B).
To further investigate the morphology of these elon-
gated E. coli cells, samples were visualized by transmis-
sion electron microscopy (TEM) (Figure 4C). Many of
the cells appeared able to successfully undergo cell divi-
sion as the invaginations of the cell wall, which precede
cell division, were observed. In contrast no such invagi-
nations of the cell wall were present in the elongated E.
coli cells indicating that cell division had been inhibited.
Lunasin does not appear to elicit an inhibitory effect on
cell division phenotype in all host cells.
Figure 4 E. coli cell morphology expressing CBD-lunasin. Light microscopy image of Gram stained E. coli BL21* (DE3) expressing (A) CBD-
lunasin fusion protein and (B) CBD alone. Note the absence of the elongated non-septate forms of E. coli BL21*(DE3) in cells expressing CBD
alone. (C) TEM image of the elongated, non-septate morphology of subsets of E. coli BL21*(DE3) expressing the CBD-lunasin fusion protein. Two
distinct regions can be identified which are indicated by white arrows. It is likely that the darker regions represent the aggregation of fusion
protein into insoluble inclusion bodies. In contrast the lighter regions are likely to represent the soluble fusion protein.
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In this work, the C. thermocellum derived CBD protein
w a su s e da saf u s i o np a r t n e rf o rt h ee x p r e s s i o no ft h e
therapeutic peptide lunasin. The CBD protein appears
to reduce the previously observed toxicity of the lunasin
peptide [15], as extremely high cell culture densities
were obtained (OD600 of 53) with correspondingly high
recovery of fusion protein. From the growth curves the
highest culture densities and yields were obtained from
cultures grown in very rich 8ZY medium supplemented
with 4 × 5052 and succinate. However, use of this med-
ium does result in a prolonged initial growth lag phase
and so simpler TB medium may prove more suitable for
large scale applications. Although the culture densities
are lower for this medium it more rapidly reaches its
maximal culture density. The culture time saved
together with the lower cost of TB medium may com-
pensate for the reduced peptide yields.
The use of the CBD fusion protein potentially offers
significant advantages for the production of lunasin and
other peptides. The ease of the batch purification proce-
dure and the high degree of purity of the final product
in conjunction with a cheap and abundant cellulose pur-
ification matrix are highly desirable for scale-up produc-
tion. One challenge with this approach is determining
efficient elution conditions that do not result in large
volumes of dilute protein. In this regard the nickel affi-
nity purification was more appropriate with around 50%
recovery of fusion protein. Improvements in peptide
recovery might be achieved by combining cellulose affi-
nity with on column cleavage followed by immobilised
metal affinity chromatography (IMAC) to remove con-
taminants. As recovery of peptide was only 60% from
the IMAC step, some of the target peptide may bind
non-specifically to the IMAC resin resulting in peptide
loss and so separation by alternative chromatographic
approaches following TEV cleavage could be explored.
A final Detoxi gel™ column would allow the removal of
endotoxins resulting in a highly purified peptide solution
that could then be used for cell-based assays and ulti-
mately in vivo models.
From visualisation of E. coli cells expressing the CBD-
lunasin, it was apparent that the lunasin peptide can
exert a significant effect on cell morphology, but this
was only apparent in a subpopulation of cells. A similar
phenotype has been observed in E. coli strains carrying
mutations in the filamentous temperature sensitive (Fts)
Z gene [16]. The FtsZ gene shares homology with the
tubulins of eukaryotic cells and has led to the proposal
that lunasin may have a similar effect on eukaryotic
cells as FtsZ mutations in bacteria [9,16]. Lunasin
expression in E. coli has a similar cytokinesis inhibitory
effect that can be prevented by the removal of the poly-
aspartyl tail of lunasin, indicating that aberrant cell divi-
sion is attributable to this acidic domain [9]. The
elongated phenotype could be due to the direct interac-
tion of lunasin with one or more of the proteins or may
be indirect due to interactions with other protein(s)
within E. coli perhaps preventing FtsZ gene transcrip-
tion. Clearly the effect on cell division is variable as this
was not observed in a recent study [11]. Our observa-
tions reveal that only a sub-population show the elon-
gated morphology. This could be due to a dosage effect
perhaps reporting the release of lunasin from the fusion
protein, such that in a subpopulation of cells higher
levels of lunasin are released and reach a threshold level
able to mediate the observed phenotype. Further investi-
gation of the difference observed between the various
lunasin expression studies with regard to aberrant cell
division would be required to understand this
phenomenon.
The altered cell morphology may explain the very high
culture densities observed as the elongated cells may
alter the relationship between OD600 and cell number.
The next stage will be to compare the efficacy of the
recombinantly produced peptide with that from native
sources such as soybean. For example through in vitro
trials on cancer cell lines such as human breast cancer
MCF-7 cells to determine whether cell division is inhib-
ited and subsequently in vivo testing perhaps utilising
skin cancer mouse models.
Conclusions
The CBD protein has been used as a successful fusion
partner for the production of the chemopreventive pep-
tide lunasin resulting in yields of peptide of upto 210
mg/L. Optical densities and protein yields were found to
be enhanced when basal media was supplemented with
4 × 5052 and with succinate. However, these yields
could potentially be increased further in bioreactors
where oxygen and nutrient levels can be tightly regu-
lated. This study highlights the potential for producing a
therapeutic peptide in a prokaryotic system and may be
of general applicability for a range of other therapeutic
peptides.
Methods
Bacterial strains, plasmids and cell culture media
E. coli X L 1B l u e( S t r a t a g e n e ,L aJ o l l a ,C A )w a su s e df o r
routine cloning. E. coli BL21Star (DE3) (Invitrogen,
Carlsbad, CA) was used as the expression strain. The
expression vector pET28c was from Novagen, Madison,
WI and pGEM-T Easy from Promega.
The auto-induction growth media Terrific Broth (TB),
4ZY, 8ZY, 8ZY supplemented with succinate were pre-
pared according to [12]. The composition of various
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and carbenicillin were added to media to a final concen-
tration of 50 μg/mL as appropriate Cultures were grown
in an orbital incubator at 37°C with shaking at 220 rpm
unless otherwise stated.
Construction of plasmid pET28c/CBD/his/TEV
We used a plasmid generated in the laboratory by Dr. J.
Riley. pET28c/rub/His/TEV was restricted with NcoI
and AatIIand treated with antarctic phosphatase (New
England BioLabs, Hitchin, UK) to generate the plasmid
backbone. A pUC57 plasmid containing the C. thermo-
cellum CBD coding sequence codon optimised for
expression in E. coli (GenScript, Piscataway, NJ) was
restricted with the same enzymes and the CBD insert
was gel extracted, purified using a QIAquick Gel Extrac-
tion Kit (Qiagen, Crawley, UK) and ligated into the
vector.
Following transformation into E. coli XL-1 blue cells,
kanamycin resistant colonies were screened by colony
PCR using T7 forward (TAATACGACTCAACTA-
TAGGG), T7 reverse (GCTAGTTATTGCTCAGCGG)
primers. Clones generating a 814 bp band were then
confirmed by DNA sequencing on an ABI 3100XL
Capillary Sequencer (DNA Sequencing Facility, Biologi-
cal Sciences, University of Leeds).
Gene synthesis by recursive PCR
In order to generate the lunasin coding sequence, recur-
sive PCR was performed with two primers, EcHisTEV-
lunF (GCGACGTCCATCACCATCACCATCAC-
GAAAACCTGTATTTTCAGAGCAAATGGC AGCAT-
CAGCAAGATAGCTGCCGCAAACAGCTG-
CAGGGCGTGAATCTGAC) and EcHisTEVlunR
(GCACAGTGACTGTTATTAATCATCGTCATCAT-
CATCGTCATCATCGCCGCGGCCC
TGAATCTTTTCCATGATATGTTTTTCG-
CACGGGGTCAGATTCACGC) possessing 13 bp com-
plementary regions at their 3’ ends (underscored).
Primers were added to a final concentration of 0.3 μM
to a PCR reaction mixture consisting of 1 × KOD Hot
Start DNA polymerase buffer (20 mM Tris-HCl (pH 7.5
at 25°C), 8 mM MgCl2, 0.5 mM DTT, 50 mg/mL BSA)
(Novagen), 0.2 mM each dNTP, 1 mM MgSO4 and 1 U
KOD Hotstart DNA polymerase and made up to 50 μL
with sterile ddH2O. PCR was performed in a G-storm
GS2 PCR machine (Gene Technologies) at 95°C for 5
min then 39-45°C for 30 s and 72°C for 1 min.
The PCR product was cloned into pGEM T easy
according to the manufacturer’ guidelines (Promega)
transformed into E. coli XL-1 blue cells. Colonies con-
taining recombinant plasmids were identified by colony
PCR, as above, with the primers T7 Forward and SP6
promoter (ATTTAGGTGACAGTATAGAATAC). The
insert was recovered by AatII and AlwNI restriction
digestion ligation into similarly digested pET28c/CBD/
His/TEVp vector. Following colony PCR screening the
sequence of pET28c/CBD/His/TEVp/lunasin was con-
firmed by DNA sequencing.
E. coli expression of pET28c constructs by auto-induction
T h ep r o t o c o l sd e s c r i b e db y[ 1 2 ]w e r ef o l l o w e d .L B
plates with kanamycin (50 μg/mL) were streaked from
glycerol stocks and grown overnight. A single colony
was used to inoculate 2 mL of LB medium with kana-
mycin (50 μg/mL and grown at 37°C, 200 rpm for 6 h.
A 200 μL aliquot of this starter culture was then used to
inoculate 400 mL of TB, 4ZY, 8ZY or 8ZY supplemen-
ted with 25 mM succinate and auto-induction media
components (Table 1) in baffled flasks. Cultures were
grown at 25°C in an orbital incubator at 250 rpm. Sam-
ples of 1 mL were taken at regular intervals and the cell
pellets stored at -20°C for time course expression analy-
sis by SDS-PAGE. After 60-96 h the cultures were har-
vested by centrifugation, 5000 × g for 20 min at 4°C and
the cell pellets stored at -80°C prior to processing.
E. coli expression of TEV protease and protein
concentration analysis
Expression of TEV protease was performed according to
the method devised by [17]. Initially two pre-cultures of
5 mL LB containing ampicillin (100 μg/mL) and chlor-
amphenicol (34 μg / m L )w e r eg r o w no v e rn i g h ta t3 7 ° C
and used to inoculate two 500 mL volumes of LB in 2 L
flasks. These cultures were grown to an OD600 of 0.6
and IPTG was added to a final concentration of 1 mM
and the temperature reduced to 20°C for 20 h. The cells
were then harvested by centrifugation at 5000 × g for 15
min (4°C) and re-suspended in 40 mL of lysis buffer (50
mM HEPES, 25% w/v sucrose, 5 mM MgCl2, 1% v/v
Triton
® X-100 at pH 8.0 supplemented with 200 units/
mL of Omnicleave nuclease (Epicentre, Cambridge, UK)
and 1 mg/mL of lysozyme, prior to use). After cell lysis
for 3 h on a ‘Roller Mixer SRT1’ (Stuart Scientific) at 4°
C cell debris was removed by centrifugation at 15,000 ×
g for 30 min. The supernatant was dialysed into 5 L of
dH20c o n t a i n i n g5 0m MN a H 2PO4, 300 mM NaCl, pH
7.0 at 4°C overnight and subsequently purified by nickel
affinity chromatography. Following purification, EDTA
and DTT were added to a concentration of 2 and 10
mM respectively. The eluate was then dialysed against 5
Lo fd H 20c o n t a i n i n g2 5m MN a H 2PO4, 200 mM NaCl,
2 mM EDTA and 2 mM DTT (pH 7.0) over night at 4°
C. Samples were concentrated to 30 μM using an ‘Ami-
con Ultra
®’ centrifugal device with a molecular cut off
point of 3500 Da.
The protein concentration was determined spectro-
photometrically and calculated using the extinction
Kyle et al. Microbial Cell Factories 2012, 11:28
http://www.microbialcellfactories.com/content/11/1/28
Page 6 of 8coefficient ε280 = 36130 M
-1 cm
-1 [17] in conjunction
with the Beer-Lambert law (A = εcl).
Analysis of soluble and insoluble cell proteins
Cells were harvested at 5000 × g for 15 min (4°C) in a
fixed angle rotor and lysed in lysis buffer as above using
5 ml/g of cell pellet for 3 h at 4°C. After centrifugation
at 15,000 × g for 30 min the supernatant represented
the soluble fraction. The pellets representing the insolu-
ble fraction was resuspended in the original volume of
lysis buffer supplemented with 8 M urea at 4°C with agi-
tation for 2 h to solubilise insoluble fusion protein.
Equal volumes of soluble and insoluble fractions were
analysed by SDS-PAGE.
SDS-PAGE analysis of protein expression and
densitometry analysis
Protein samples were heated at 95°C for 10 min in load-
ing buffer consisting of 40% SDS, 20% b-mercaptoetha-
nol, 20% glycerol, and 0.01% of bromophenol blue in 1
M Tris-HCl (pH 6.8) before analysis on NuPAGE
® 12%
Bis-Tris gels (Invitrogen, Paisley, UK) at 200 V for 45
min. Protein bands were visualised using SimplyBlue™
SafeStain (Invitrogen, Paisley, UK) and protein concen-
trations estimated by densitometry using the AlphaIma-
ger Spot Denso software. The intensities of the bands
were compared to those of known concentrations of low
molecular weight protein standards (GE healthcare).
Protein purification
Batch binding to cellulose phosphate
Cellulose phosphate was added (200 mg/mL) directly to
soluble cell extract samples and incubated at room tem-
perature with agitation for 2 h to allow binding of CBD
to the cellulose. The cellulose was then washed twice
with 10 mM sodium phosphate buffer (pH 8.0), with
gentle agitation for 20 min followed by centrifugation at
7000 × g for 10 min at 4°C and the wash buffer was
decanted. Finally, the bound protein was eluted by addi-
tion of cold ddH20 and incubation for 1 h at 4°C. This
step was repeated up to three times to improve protein
recovery. Resulting purified fractions were analysed by
SDS-PAGE. Where protein solutions were too dilute
‘Microcon
®’ and ‘Amicon Ultra
®’ centrifugal devices was
used according to the manufacturers’ guidelines, for
volumes below and above 1 mL respectively, to concen-
trate the samples.
Nickel affinity chromatography (Ni-NTA)
Purification of His-tagged polypeptides and proteins was
achieved by using a 5 mL HiTrap™ column containing
Chelating Sepharose™ High Performance (GE Health-
care). Protein samples were resuspended in binding buf-
fer (20 mM Tris-HCl, 0.5 M NaCl, 5 mM imidazole, 1
mM b-mercaptoethanol, pH 8) and loaded onto the
column followed by extensive washing with binding buf-
fer containing 20 mM imidazole to remove non-specifi-
cally bound proteins. The bound proteins were eluted
by applying a 0-100% gradient (20 mM - 500 mM) over
50 mL of buffer and 1 mL fractions were collected.
Fractions containing protein were analysed by SDS-
PAGE analysis. Protein concentrations were determined
by using the Bradford assay reagent (Sigma-Aldrich).
TEV cleavage of peptide constructs
Cleavage experiments were performed according to [17].
TEV protease was used at a final concentration of 700
nM in TEV protease cleavage buffer (25 mM NaPi, 125
mM NaCl, and 5 mM DTT, pH 7.4) at room
temperature.
Mass spectrometry
Peptide samples were first concentrated using C18 Zip-
Tip (Millipore UK, Ltd.) and eluted in 50% methanol/
0.1% aqueous formic acid and then analysed by positive
ionisation nanoelectrospray using an LCT Premier mass
spectrometer (Waters Corporation, Manchester, UK).
Samples were infused using a NanoMate (Advion Bios-
ciences Inc., Ithaca, NY) autosampler and ionisation
interface which was maintained at 4°C. A capillary vol-
tage of 1.8 kV was set with a nitrogen gas flow of 0.4
psi for sample introduction and ionisation. The sam-
pling cone voltage was optimised at 20 V, Ion Guide 1
w a sa t1 3 0Va n dA p e r t u r e1w a sa t6 0V .D a t aw e r e
acquired over the m/z range 500-5000, and data proces-
sing was performed using the MassLynx software sup-
plied with the mass spectrometer. An external
calibration using sodium iodide clusters was applied to
the data.
Gram-staining and light microscopy
Cultures (10 μl) containing E. coli BL21* (DE3) was
smeared onto a slide and heat fixed. Crystal violet solu-
tion was applied and allowed to stand for 1 min before
extensive washing. The slide was then flooded with
iodine solution and allowed to stand for 1 min before
rinsing again. The slide was then decolourised with acet-
one for 5 s and immediately rinsed with distilled water.
Safranin was applied and allowed to stand for 30 s
before a final rinse with distilled water. Bacterial slides
were examined using a light microscope (Olympus,
BX51) under a 100 × objective.
Transmission electron microscopy
E. coli cells in growth media were harvested by centrifu-
gation at 17,900 × g for 2 min in microcentrifuge tubes.
Cells were subsequently washed twice with dH2Ot h e n
fixed with 2.5% glutaraldehyde for 3 h followed by wash-
ing twice with 0.1 M phosphate buffer (pH 7.0) for 30
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min to collect the cells. Cell samples were incubated in
1.0% osmium tetraoxide solution overnight followed by
washing twice with 0.1 M phosphate buffer and har-
vested by centrifugation at 6,000 × g for 5 min.
Samples were then dehydrated by incubating in
ascending concentrations of ethanol (20%, 40%, 60%,
80%, and 100% twice) for 30 min each. Dehydration of
the samples was followed by two incubations in propy-
lene oxide for 30 min followed by centrifugation at
6,000 × g for 5 min to harvest the cells. Embedding was
achieved by incubating in a 50%:50% mix of propylene
oxide and araldite overnight. Samples were then incu-
bated in a 75%: 25% araldite:propylene mix for 3 h.
Finally, samples were re-suspended in fresh araldite and
transferred to embedding moulds and incubated over-
night at 60°C to set. The embedded cells were sectioned
using a microtome and placed onto Glow-discharged
carbon coated copper TEM grids for visualization using
a Philips CM10 TEM operating at 80 kV.
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